IRIS

POGGESI, ITALO

POGGESI, ITALO  

DIPARTIMENTO DI INGEGNERIA INDUSTRIALE E DELL'INFORMAZIONE  

Mostra records
Risultati 1 - 19 di 19 (tempo di esecuzione: 0.041 secondi).
Titolo Data di pubblicazione Autore(i) File
A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension 1-gen-2021 Bartolucci, R.; Dosne, A.; Csonka, D.; Perez-Ruixo, J. J.; Magni, P.; Poggesi, I.
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib 1-gen-2022 Tosca, E. M.; Terranova, N.; Stuyckens, K.; Dosne, A. G.; Perera, T.; Vialard, J.; King, P.; Verhulst, T.; Perez-Ruixo, J. J.; Magni, P.; Poggesi, I.
Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis 1-gen-2015 Sardu, M. L.; Poggesi, I.; Nicolao, De
Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis 1-gen-2015 Sardu, M. L.; Poggesi, I.; Nicolao, De
Biomarker-driven models of tumor growth inhibition in preclinical animal studies 1-gen-2012 Sardu, MARIA LUISA; Russu, Alberto; DE NICOLAO, Giuseppe; Poggesi, Italo
Current mathematical models for cancer drug discovery 1-gen-2017 Carrara, Letizia; Lavezzi, SILVIA MARIA; Borella, Elisa; DE NICOLAO, Giuseppe; Magni, Paolo; Poggesi, Italo
Integration of response, tolerability and dropout in flexible-dose trials: a case study in depression 1-gen-2011 Russu, Alberto; Marostica, Eleonora; DE NICOLAO, Giuseppe; A. C., Hooker; Poggesi, Italo; R., Gomeni; S., Zamuner
Mathematical modeling of efficacy and safety for anticancer drugs clinical development 1-gen-2018 Lavezzi, S. M.; Borella, E.; Carrara, L.; De Nicolao, G.; Magni, P.; Poggesi, I.
Method to evaluate the systemic exposure in toxicological and pharmacological studies 1-gen-2001 Bellazzi, Riccardo; DE NICOLAO, Giuseppe; Magni, Paolo; Poggesi, I.; Rocchetti, M.
Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity 1-gen-2021 Tosca, E. M.; Bartolucci, R.; Magni, P.; Poggesi, I.
Pharmacokinetic-Pharmacodynamic Modeling in Drug Development with Special Reference to Oncology 1-gen-2016 Sardu, MARIA LUISA; DE NICOLAO, Giuseppe; Poggesi, Italo
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies 1-gen-2015 Marostica, Eleonora; Sukbuntherng, Juthamas; Loury, David; De Jong, Jan; De Trixhe, Xavier Woot; Vermeulen, An; DE NICOLAO, Giuseppe; O'Brien, Susan; Byrd, John C.; Advani, Ranjana; Mcgreivy, Jesse; Poggesi, Italo
Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs 1-gen-2018 Borella, E.; Poggesi, I.; Magni, P.
Predictive assessments of pharmacokinetic alterations in subjects with renal disease 1-gen-2015 Borella, Elisa; Poggesi, Italo; Magni, Paolo
Steady-state equivalence of drug- and biomarker driven models in tumor growth experiments 1-gen-2014 Sardu, MARIA LUISA; Poggesi, Italo; DE NICOLAO, Giuseppe
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial 1-gen-2019 Lavezzi, S. M.; de Jong, J.; Neyens, M.; Cramer, P.; Demirkan, F.; Fraser, G.; Bartlett, N.; Dilhuydy, M. -S.; Loscertales, J.; Avigdor, A.; Rule, S.; Samoilova, O.; Goy, A.; Ganguly, S.; Salman, M.; Howes, A.; Mahler, M.; De Nicolao, G.; Poggesi, I.
Tumor growth modelling for drug development 1-gen-2014 Simeoni, Monica; Magni, Paolo; Poggesi, Italo; DE NICOLAO, Giuseppe; M., Rocchetti
Tumor-growth inhibition in preclinical animal studies: steady-state analysis of biomarker-driven models 1-gen-2013 Sardu, MARIA LUISA; Russu, Alberto; Poggesi, Italo; DE NICOLAO, Giuseppe
Use of Physiology-Based Elements to Predict the Pharmacokineticsof New Drugs 30-gen-2017 Poggesi, Italo